Ketoconazole therapy of progressive coccidioidomycosis

Comparison of 400- and 800-mg doses and observations at higher doses
      This paper is only available as a PDF. To read, Please Download here.


      One hundred and twelve patients with progressive pulmonary, skeletal, or soft tissue infections caused by Coccidioides immitis were randomly assigned to treatment with 400 or 800 mg per day dosages of ketoconazole. During therapy, if response was unsatisfactory, the protocol provided for treatment with higher doses. With 400 mg, ketoconazole resulted in 23.2 percent successes, which was similar to 32.1 percent successes with 800-mg treatments (p = 0.29). An additional six of 23 patients in whom initial therapy failed and who later received 1,200 or 1,600 mg per day of ketoconazole also showed improvement. However, among patients completing successful courses of therapy, relapses were more frequent in those requiring higher than 400-mg dosages for their success. From these studies, it is concluded that ketoconazole in doses above those currently recommended offer little or no benefit for most patients with non-meningeal forms of coccidioidomycosis.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Stevens DA
        Coccidioidomycosis and the indications for chemotherapy.
        Drugs. 1983; 26: 334-336
        • Drutz DJ
        Amphotericin B in the treatment of coccidioidomycosis.
        Drugs. 1983; 26: 337-346
        • Galgiani JN
        Ketoconazole in the treatment of coccidioidomycosis.
        Drugs. 1983; 26: 355-363
        • Stevens DA
        Ketoconazole metamorphosis.
        in: An antimicrobial becomes an endocrine drug. 6th ed. Arch Intern Med. 145. 1985: 813-815
        • Lewis JH
        • Zimmerman HJ
        • Benson GD
        • Ishak KG
        Hepatic injury associated with ketoconazole therapy.
        in: Analysis of 33 cases. 6th ed. Gastroenterology. 86. 1984: 503-513
        • Sugar AM
        • Alsip S
        • Galgiani JN
        • et al.
        Pharmacology and toxicity of high dose ketoconazole.
        Antimicrob Agents Chemother. 1987; 31: 1874-1878
        • Dismukes WE
        • Bennett JE
        • Drutz DJ
        • Graybill JR
        • Remington JS
        • Stevens DA
        Criteria for evaluation of therapeutic response to antifungal drugs.
        Rev Infect Dis. 1980; 2: 534-544
        • Snedecor GW
        • Cochran WG
        Statistical methods.
        6th ed. Iowa State University Press, Ames, Iowa1967
        • Kaplan EL
        • Meier P
        Nonparametric estimation from incomplete observations.
        J Am Statistics Ass. 1958; 53: 457-481
        • Ostle B
        • Mensing P
        Statistics in research.
        in: Iowa State University Press, Ames, Iowa1975: 128-131
        • Catanzaro A
        • Einstein H
        • Levine HB
        • et al.
        Ketoconazole for treatment of disseminated coccidioidomycosis.
        Ann Intern Med. 1982; 96: 436-440
        • Ross JB
        • Levine HB
        • Catanzaro A
        • et al.
        Ketoconazole for treatment of chronic pulmonary coccidioidomycosis.
        Ann Intern Med. 1982; 96: 440-443
        • Defelice R
        • Galgiani JN
        • Campbell SC
        • et al.
        Ketoconazole treatment of nonprimary coccidioidomycosis.
        in: Evaluation of 60 patients during three years of study. 7th ed. Am J Med. 72. 1982: 681-687
        • Graybill JR
        • Craven PC
        • Donovan W
        • Matthew EB
        Ketoconazole therapy for systemic fungal infections: inadequacy of standard dosage regimens.
        Am Rev Respir Dis. 1982; 126: 171-174
        • Dismukes WE
        • Stamm AM
        • Graybill JR
        • et al.
        Treatment of systemic mycoses with ketoconazole: emphasis on toxicity and clinical response in 52 patients.
        Ann Intern Med. 1983; 98: 13-20
        • Stevens DA
        • Stiller RL
        • Williams PL
        • Sugar AM
        Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis.
        Am J Med. 1983; 74 (suppl): 58-63